Australia markets open in 5 hours 13 minutes
  • ALL ORDS

    6,905.30
    +248.90 (+3.74%)
     
  • AUD/USD

    0.6474
    -0.0045 (-0.69%)
     
  • ASX 200

    6,699.30
    +242.40 (+3.75%)
     
  • OIL

    86.49
    +2.86 (+3.42%)
     
  • GOLD

    1,729.90
    +27.90 (+1.64%)
     
  • BTC-AUD

    30,828.52
    +433.19 (+1.43%)
     
  • CMC Crypto 200

    453.46
    +8.03 (+1.80%)
     

A number of insiders bought Oventus Medical Limited (ASX:OVN) stock last year, which is great news for shareholders

·3-min read

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Oventus Medical Limited (ASX:OVN), that sends out a positive message to the company's shareholders.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for Oventus Medical

Oventus Medical Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when insider Melvyn Bridges bought AU$145k worth of shares at a price of AU$0.11 per share. That means that an insider was happy to buy shares at above the current price of AU$0.022. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

Oventus Medical insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Does Oventus Medical Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Oventus Medical insiders own 21% of the company, worth about AU$1.1m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Oventus Medical Insiders?

The fact that there have been no Oventus Medical insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders own shares in Oventus Medical and we see no evidence to suggest they are worried about the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Oventus Medical. Our analysis shows 6 warning signs for Oventus Medical (4 are a bit concerning!) and we strongly recommend you look at these before investing.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.